1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 12,500 | 12,600 | 07.08. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 23.07. | B.Riley initiates Agomab Therapeutics stock with buy rating | 1 | Investing.com | ||
| 23.06. | Agomab gibt Design für Phase-2b-Studie zu Morbus-Crohn-Medikament bekannt | 4 | Investing.com Deutsch | ||
| 23.06. | Agomab announces Phase 2b study design for Crohn's disease drug | 1 | Investing.com | ||
| 23.06. | Agomab Therapeutics Aligns With FDA On Design Of Phase 2b NOV-ERA Study With Ontunisertib | 1 | Benzinga.com | ||
| 23.06. | Agomab Therapeutics NV - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 23.06. | AgomAb Therapeutics NV: Agomab Announces Design of NOV-ERA Phase 2b Study with Ontunisertib in Fibrostenosing Crohn's Disease | 495 | GlobeNewswire (Europe) | -- Regulatory alignment with U.S. Food and Drug Administration (FDA) on key elements of NOV-ERA Phase 2b study design, including novel primary endpoint of endoscopic passability -- -- Study initiation... ► Artikel lesen | |
| 22.06. | H.C. Wainwright initiates Agomab stock coverage with buy rating | 1 | Investing.com | ||
| 27.05. | Agomab Therapeutics NV - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| AGOMAB THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 27.05. | AgomAb Therapeutics NV: Agomab Announces Results of Annual General Meeting | 180 | GlobeNewswire (Europe) | Antwerp, Belgium, May 27, 2026 - Agomab Therapeutics NV (Nasdaq: AGMB) ("Agomab"), a clinical-stage biopharmaceutical company focused on fibro-inflammation, today announced the results of its Annual... ► Artikel lesen | |
| 24.04. | Agomab Therapeutics NV - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 24.04. | AgomAb Therapeutics NV: Agomab Reports Full Year 2025 Financial Results and Confirms 2026 Outlook | 302 | GlobeNewswire (Europe) | -- Cash and Cash Investments at December 31, 2025 of €116.5 Million and Gross Proceeds of $208 Million from Initial Public Offering (IPO) Expected to Extend Cash Runway into First Half of 2029 --... ► Artikel lesen | |
| 23.04. | Agomab Therapeutics NV - 20-F, Annual and transition report of foreign private issuers | - | SEC Filings | ||
| 26.03. | Agomab receives U.S. patent for lung fibrosis drug candidate | 3 | Investing.com | ||
| 26.03. | AgomAb Therapeutics N.V.: Agomab Receives U.S. Patent for AGMB-447, its Inhaled Lung-restricted Small Molecule Inhibitor of ALK5 in Development for the Treatment of Idiopathic Pulmonary Fibrosis | 179 | GlobeNewswire (Europe) | Antwerp, Belgium, March 26, 2026 - Agomab Therapeutics NV (Nasdaq: AGMB) ("'Agomab'"), a clinical-stage biopharmaceutical company focused on fibrosis, today announced that the United States Patent... ► Artikel lesen | |
| 11.03. | Agomab Therapeutics NV - S-8, Securities to be offered to employees in employee benefit plans | - | SEC Filings | ||
| 05.03. | Agomab Therapeutics NV - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 03.03. | Morgan Stanley initiates Agomab Therapeutics stock with overweight rating | 5 | Investing.com | ||
| 03.03. | Morgan Stanley stuft Agomab Therapeutics mit "Overweight" ein und sieht 73 % Kurspotenzial | 2 | Investing.com Deutsch | ||
| 03.03. | JPMorgan initiates Agomab Therapeutics stock at Overweight | 2 | Investing.com | ||
| 03.03. | JPMorgan startet Coverage für Agomab Therapeutics mit "Overweight" | 2 | Investing.com Deutsch |
1 2 Weiter >>
24 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIOFRONTERA | 2,490 | -2,73 % | PTA-Adhoc: Biofrontera AG: Biofrontera AG beschließt Vorbereitung des Wechsels vom regulierten Markt (Prime Standard) in das Börsensegment Scale | DJ PTA-Adhoc: Biofrontera AG: Biofrontera AG beschließt Vorbereitung des Wechsels vom regulierten Markt (Prime Standard) in das Börsensegment Scale
Veröffentlichung von Insiderinformationen gemäß... ► Artikel lesen | |
| BIONXT SOLUTIONS | 0,207 | +5,08 % | Viking Therapeutics, BioNxt Solutions, Bausch Health - Studienerfolg entfacht neue Fantasie | Die Pharmaindustrie steht vor einer neuen Wachstumsphase. Milliarden fließen in innovative Therapien, moderne Arzneimitteltechnologien und die Weiterentwicklung etablierter Medikamente. Besonders dynamisch... ► Artikel lesen | |
| BIOCRYST PHARMACEUTICALS | 8,172 | +0,79 % | Biocryst outlines $690M-$715M 2026 total revenue guidance with operating costs at $420M-$440M | ||
| ARROWHEAD PHARMACEUTICALS | 74,84 | -1,29 % | Arrowhead plans sNDA by end of 2026 as SHASTA shows 79%-81% triglyceride reductions and 78% fewer pancreatitis events | ||
| ARBUTUS BIOPHARMA | 3,980 | -0,50 % | Arbutus, Genevant File International Lawsuits Against Pfizer, BioNTech | NEW YORK CITY (dpa-AFX) - Arbutus Biopharma (ABUS), and its licensee, Genevant Sciences - a unit of Roivant Sciences (ROIV)), announced the filing of three international lawsuits seeking to... ► Artikel lesen | |
| ATAIBECKLEY | 6,250 | -0,79 % | Laufende Fusionskontrollverfahren: Eli Lilly and Company, Indianapolis, IN/USA; Erwerb sämtlicher Anteile an und alleiniger Kontrolle über die AtaiBeckley Inc., New York/USA | Datum der Anmeldung:23.07.2026Aktenzeichen:B3-85/26Unternehmen:Eli Lilly and Company, Indianapolis, IN/USA; Erwerb sämtlicher Anteile an und alleiniger Kontrolle über die AtaiBeckley Inc., New York/USAProduktmärkte:Biotechnologie... ► Artikel lesen | |
| ALDEYRA | 1,350 | 0,00 % | Aldeyra Therapeutics, Inc. - 10-Q, Quarterly Report | ||
| ABCELLERA BIOLOGICS | 5,950 | -0,67 % | AbCellera rises as it will release phase 2 results of menopause asset | ||
| ADAPTIVE BIOTECHNOLOGIES | 21,370 | -0,84 % | Adaptive Biotechnologies Corp - 10-Q, Quarterly Report | ||
| BIOMERIEUX | 73,05 | 0,00 % | BioMerieux H1 Net Sales Slip On Foreign Exchange Impact; Backs Annual Sales Growth Outlook | PARIS (dpa-AFX) - BioMérieux SA (EYWN.MU, BIM.PA), a French biotechnology company, on Tuesday reported an increase in net income for the first half of fiscal 2026, helped by a drop in amortization... ► Artikel lesen | |
| BEAM THERAPEUTICS | 27,480 | 0,00 % | Beam Therapeutics Reports Second Quarter 2026 Financial Results and Announces First Patient Dosed in Global Pivotal Cohort of BEAM-302 Trial in Alpha-1 Antitrypsin Deficiency (AATD) | Updated BEAM-302 Phase 1/2 Clinical Data Selected for Late-Breaking Oral Presentation at the European Respiratory Society (ERS) Congress 2026 Dosing Complete for All Adult and Adolescent Patients... ► Artikel lesen | |
| AC IMMUNE | 2,020 | -0,98 % | AC Immune SA: AC Immune First Half 2026 Financial and Corporate Update | AC Immune First Half 2026 Financial and Corporate Update Focused portfolio of wholly-owned programs approach near-term clinical catalysts as partnered programs generate milestone payments Key advances... ► Artikel lesen | |
| 10X GENOMICS | 44,700 | -0,80 % | 10x Genomics, Inc.: 10x Genomics Reports Second Quarter 2026 Financial Results | PLEASANTON, Calif., Aug. 6, 2026 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), the life science technology leader focused on accelerating science and advancing... ► Artikel lesen | |
| BIOXCEL THERAPEUTICS | 0,780 | -1,02 % | BioXcel Therapeutics, Inc. - 8-K, Current Report | ||
| AGIOS | 27,800 | 0,00 % | Agios Pharmaceuticals, Inc.: Agios Reports Second Quarter 2026 Financial Results and Provides Business Update | Mitapivat (PYRUKYND and AQVESME) delivered worldwide net revenues of $44.7 million in the second quarter of 2026, compared to $12.5 million in the second quarter of 2025Strong U.S. commercial launch... ► Artikel lesen |
AGOMAB THERAPEUTICS NV ADR gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 11,900 Euro und damit -5,56 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu AGOMAB THERAPEUTICS NV ADR finden Sie auf Wallstreet Online.